Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options

References

• A clinical evaluation of the International lymphoma study group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:3909-18
   PubMed Web of Science ®Google Scholar
• Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-52
   PubMed Web of Science ®Google Scholar
• Keegan THM, McClure LA, Foran JM, Clarke CA. Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population based study. J Clin Oncol 2009;27:3044-51
   PubMed Web of Science ®Google Scholar
• Bierman PJ, Sweetenham JW, Loberiza FR, et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin’s lymphoma: a comparison with allogeneic and autologous transplantation. The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003;21:3744-53
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-69
   PubMed Web of Science ®Google Scholar
• Harris NL, Swerdlow SH, Jaffe ES, et al. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO Classification of tumours of haematopoietic and lymphoid tissues. IARC; Lyon: 2008. p. 220-6
   Google Scholar
• Bodor C, Grossmann V, Popov N, et al. EZH2 mutation are frequent and represent an early event in follicular lymphoma. Blood 2013;122:3165-8
   PubMed Web of Science ®Google Scholar
• Ansell SM. Malignant B cells at the helm in follicular lymphoma. J Clin Oncol 2013;31:2641-2
   PubMed Web of Science ®Google Scholar
• Kiaii S, Clear AJ, Ransay AG, et al. Follicular lymphoma cells induce changes in T-cell gene expression and function: Potential impact on survival and risk of transformation. J Clin Oncol 2013;31:2654-61
   PubMed Web of Science ®Google Scholar
• De Angelis F, Foà R. Follicular lymphoma. Exp Oncol 2012;34(4):380-3
   PubMedGoogle Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Solal-Céligny Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27(27):4555-62
   PubMed Web of Science ®Google Scholar
• Farinha P, Masoudi H, Skinnider BF, et al.Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106(6):2169-74
   PubMed Web of Science ®Google Scholar
• Denham JW, Denham E, Dear KB, et al. The follicular non-Hodgkin’s Lymphomas-1.The possibility of cure. Eur J cancer 1996;32A(3):470-9
   Google Scholar
• Pugh TJ, Ballonoff A, Newman F, et al. Improved survival in patients with early stage low grade follicular lymphoma treated with radiation: A Surveillance, Epidemiology, and End Results database analysis. Cancer 2010;116:3843-51
   PubMed Web of Science ®Google Scholar
• Vaughan Hudson G, MacLennan KA, Anderson L, Linch DC. Clinical stage I non-Hodgkin’s lymphoma; long term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994;69:1088-93
   PubMed Web of Science ®Google Scholar
• MacManus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996;14:1282-90
   PubMed Web of Science ®Google Scholar
• Petersen PM, Gospodarowicz R, Tsang R, et al. Long term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone. J Clin Oncol 2004;22:6521
   Google Scholar
• Kelsey SM, Newland AC, Hudson GV, et al. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol 1994;11:19-25
   PubMed Web of Science ®Google Scholar
• Seymour JF, Pro B, Fuller LM, et al. Long term follow-up of a prospective study of combined modality therapy for stage I-II indolent non- Hodgkin’s lymphoma. J Clin Oncol 2003;21:2115-22
   PubMed Web of Science ®Google Scholar
• Besa PC, McLaughlin PW, Cox JD, Fuller LM. Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer 1995;75(9):2361-7
   PubMed Web of Science ®Google Scholar
• Janikova A, Bortlicek Z, Campr V, et al. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy? Leuk Lymphoma 2015:1-7
   Google Scholar
• Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non- Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004;22:1454-9
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved Survival in Patients With Early Stage Low-Grade Follicular Lymphoma Treated With Radiation A Surveillance, Epidemiology, and End Results Database Analysis. Cancer 2010;116(16):3843-51
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 2012;30(27):3368-75
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516-22
   PubMed Web of Science ®Google Scholar
• Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988;25:11-16.suppl 2
   PubMed Web of Science ®Google Scholar
• Webster K, Cella D. Quality of life in patients with low-grade non-Hodgkin’s lymphoma. Oncology (Williston Park) 1998;12(5):697-714
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997;15(3):1110-17
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, et al. An intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non bulky follicular lymphoma. A preliminary analysis [abstract]. Blood (ASH Annual Meeting Abstracts) 2010. 116:5-24
   Google Scholar
• Ardeshna KM, Qian W, Stephens R, et al. Preliminary results of quality of life (QOL) analysis from the intergroup phase III randomized trial of rituximab versus a watch and wait approach in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma. Ann Oncol 2011;22:88
   Web of Science ®Google Scholar
• Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696-704
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Pulsoni A, et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II nonrandomised trial (FLUMIZ). Lancet Oncol 2008;9:352-8
   PubMed Web of Science ®Google Scholar
• Link BK, Martin P, Kaminski MS, et al. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol 2010;28:3035-41
   PubMed Web of Science ®Google Scholar
• Conconi A, Motta M, Bertoni F, et al. Patterns of survival of follicular lymphomas at a single institution through three decades. Leuk Lymphoma 2010;51(6):1028-34
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26(28):4579-86
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106(12):3725-32
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Study group indolent Lymphomas (StiL).Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent andmantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381(9873):1203-10
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East german study group hematology and oncology study east german study group hematology and oncology study. J Clin Oncol 2007;25(15):1986-92
   PubMed Web of Science ®Google Scholar
• Lenz G, Hiddemann W, Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004;101:883-93
   PubMed Web of Science ®Google Scholar
• Montoto S, Moreno C, Domingo-Domenech E, et al. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica 2008;93:207-14
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Marcus R, et al. On behalf of the ESMO Guidelines Working Group Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(suppl 3)
   Google Scholar
• Zelenetz AD, Gordon LI, Wierda WG, et al. Non-Hodgkin’s lymphomas, version 2.2014. J Natl Compr Canc Netw 2014;12(6):916-46
   PubMed Web of Science ®Google Scholar
• Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013;31(12):1506-13
   PubMed Web of Science ®Google Scholar
• Baldo P, Rupolo M, Compagnoni A, et al. Interferon-alpha for maintenance of follicular lymphoma. Cochrane Database Syst Rev 2010
   Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103(12):4416-23
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496. Study.J Clin Oncol 2009;27(10):1607-14
   PubMed Web of Science ®Google Scholar
• Van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-301
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42-51
   PubMed Web of Science ®Google Scholar
• Cole BF, Solal-Céligny P, Gelber RD, et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol 1998;16(7):2339-44
   PubMed Web of Science ®Google Scholar
• Rossi G, Marcheselli L, Dondi A, et al. The use of anthracycline at first-line compared to alkylating agents or nucleoside analogsimproves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. Am J Hematol 2015;90(1):56-61
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004;104(9):2667-74
   PubMed Web of Science ®Google Scholar
• Gyan E, Foussard C, Bertrand P, et al. Groupe ouest-est des leucémies et des autres maladies du sang (GOELAMS) High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009;113(5):995-1001
   PubMed Web of Science ®Google Scholar
• Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 2006;108(8):2540-4
   PubMed Web of Science ®Google Scholar
• Ladetto M, De Marco F, Benedetti F, et al. Gruppo italiano trapianto di midollo osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008;111(8):4004-13
   PubMed Web of Science ®Google Scholar
• Laudi N, Arora M, Burns LJ, et al. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005;11(2):129-35
   PubMed Web of Science ®Google Scholar
• Itchaki G, Gafter-Gvili A, Lahav M, et al. Anthracycline-containing regimens for treatment of follicular lymphoma in adults. Cochrane Database Syst Rev 2013;7:CD008909
   Google Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014;123(19):2944-52
   PubMed Web of Science ®Google Scholar
• Nickenig C, Dreyling M, Hoster E, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone,chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. Cancer 2006;107(5):1014-22
   PubMed Web of Science ®Google Scholar
• Buske C, Gisselbrecht C, Gribben J, et al. Refining the treatment of follicular lymphoma. Leukemia Lymphoma 2008;49(Suppl 1):18-26
   PubMed Web of Science ®Google Scholar
• Cheson BD, Friedberg JW, Kahl BS, et al. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractoryindolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010;10(6):452-7
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 2005;23:3383-9
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204-10
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory,indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010;116:106-14
   PubMed Web of Science ®Google Scholar
• Koenigsmann M, Knauf W, Herold M, et al. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma a multicenter phase I/II trial of the East German Society of Hematology and Oncology (OSHO). Leuk Lymphoma 2004;45:1821-7
   PubMed Web of Science ®Google Scholar
• Weide R, Hess G, Koppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007;48:1299-306
   PubMed Web of Science ®Google Scholar
• Knospe WH, Loeb VJr. Biweekly chlorambucil treatment of lymphocytic lymphoma. Cancer Clin Trials 1980;3(4):329-36
   PubMedGoogle Scholar
• Stolzenbach G, Garbrecht M. Intermittent combination chemotherapy with chlorambucil and prednisone of low-grade malignant non-Hodgkin’s lymphomas according to the Kiel classification. J Cancer Res Clin Oncol 1979;93(2):189-94
   PubMed Web of Science ®Google Scholar
• Bagley CMJr, Devita VTJr, Berard CW, Canellos GP. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide,vincristine, and prednisone. Ann Intern Med 1972;76:227-34
   PubMed Web of Science ®Google Scholar
• Lister TA, Cullen MH, Beard ME, et al. Comparison of combined and single-agent chemotherapy in non-Hodgkin’s lymphoma of favourable histological type. Br Med J 1978;1:533-7
   PubMed Web of Science ®Google Scholar
• Manoharan A. Long-term maintenance therapy with weekly chlorambucil in patients with symptomatic or progressive follicular lymphoma. Leuk Lymphoma 2004;45(6):1305-6
   PubMed Web of Science ®Google Scholar
• Jones SE, Rosenberg SA, Kaplan HS, et al. Non-Hodgkin’s lymphomas. Cancer 1972;30(1):31-8
   Google Scholar
• Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 2003;21(1):5-15
   PubMed Web of Science ®Google Scholar
• Martinelli G, Montoro J, Vanazzi A, et al. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin’slymphoma: a retrospective single-centre study. Hematol Oncol 2014
   Google Scholar
• Zinzani PL. Non-Hodgkin’s lymphoma: the evolving role of purine analogues. Best Pract Res Clin Haematol 2002;15(3):505-16
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996;14(4):1262-8
   PubMed Web of Science ®Google Scholar
• Lenz G, Hiddemann W, Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004;101:883-93
   PubMed Web of Science ®Google Scholar
• Tam CS, Wolf M, Prince HM, et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006;106:2412-20
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Bendandi M, Gherlinzoni F, et al. FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin’s lymphoma. Haematologica 1996;81(2):168-71
   PubMed Web of Science ®Google Scholar
• Bocchia M, Bigazzi C, Marconcini S, et al. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin’s lymphomas. Haematologica 1999;84(8):716-20
   PubMed Web of Science ®Google Scholar
• Morschhauser F. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d’Etude des Lymphomes de l’Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS). Cancer 2010
   Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-8
   PubMed Web of Science ®Google Scholar
• Saven A, Piro LD 2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders.. Hematol Cell Ther 1996;38(Suppl 2):S93-101
   PubMedGoogle Scholar
• Laurencet FM, Zulian GB, Guetty-Alberto M, et al. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer 1999;79(7-8):1215-19
   PubMed Web of Science ®Google Scholar
• Robak T, Błoński JZ, Kasznicki M, et al. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia 2001;15(10):1510-16
   PubMed Web of Science ®Google Scholar
• Duggan DB, Anderson JR, Dillman R, et al. 2’ Deoxycoformycin (pentostatin) for refractory non-Hodgkin’s lymphoma: a CALGB phase II study. Med Pediatr Oncol 1990;18(3):203-6
   PubMedGoogle Scholar
• Ho AD, Hensel M. Pentostatin for the treatment of indolent lymphoproliferative disorders. Semin Hematol 2006;43(2 Suppl 2):S2-10
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706-14
   PubMed Web of Science ®Google Scholar
• Montoto S, Corradini P, Dreyling M, et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus projectof the EBMT-Lymphoma Working Party. Haematologica 2013;98(7):1014-21
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997;90:2188-95
   PubMed Web of Science ®Google Scholar
• Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-66
   PubMed Web of Science ®Google Scholar
• Colombat P, Brousse N, Salles G, et al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol 2012;23(9):2380-5
   PubMed Web of Science ®Google Scholar
• Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol 2014;32(28):3096-102
   PubMed Web of Science ®Google Scholar
• Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012;119:5126-32
   PubMed Web of Science ®Google Scholar
• Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS study [abstract]. Blood (ASH Annual Meeting Abstracts) 2011. 118:269
   Google Scholar
• Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase I/II trial. Blood 2008;111:5486-95
   PubMed Web of Science ®Google Scholar
• Leonard J, Friedberg J, Younes A, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;18:1216-23
   PubMed Web of Science ®Google Scholar
• Leonard J, Schuster S, Emmanouilides C, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008;113:2714-23
   PubMed Web of Science ®Google Scholar
• Grant B, Leonard J, Johnson J, et al. Combination biologic therapy as initial treatment for follicular lymphoma: initial results from CALGB 50701 - a phase II trial of extended induction epratuzumab (anti-CD22) and rituximab (anti-CD20). ASH Ann Meet Abstr 2010. 116:427
   Google Scholar
• Czuczman M, Thall A, Witzig T, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005;23:4390-8
   PubMed Web of Science ®Google Scholar
• Smith S, van Besien K, Karrison T, et al. Temsirolimus has activity in non-mantle cell non- Hodgkin’s lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010;28:4740-6
   PubMed Web of Science ®Google Scholar
• Witzig T, Reeder C, LaPlant B, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25:341-7
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88-94
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008-18
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-hodgkin lymphomas (Yosemite). Available from: https://clinicaltrials.gov/ct2/show/NCT01732913
   Google Scholar
• Davids MS. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma FL) at higher cohort doses. J Clin Oncol 2014;32:abst 8522
   Google Scholar
• Witzig T, Wiernik P, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol 2009;27:5404-9
   PubMed Web of Science ®Google Scholar
• Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014;15(12):1311-18
   PubMed Web of Science ®Google Scholar
• Tuscano JM, Dutia M, Chee K, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol 2014;165(3):375-81
   PubMed Web of Science ®Google Scholar
• Leonard J, Jung S, Johnson J, et al. CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. ASCO Meeting Abstracts 2012;30(15 Suppl):8000
   Google Scholar
• A phase 3 open label randomized study to compare the efficacy and safety of rituximab plus lenalidomide (CC-5013) versus rituximab plus chemotherapy followed by rituximab in subjects with previously untreated follicular lymphoma (RELEVANCE). Available from: https://clinicaltrials.gov/ct2/show/NCT01650701
   Google Scholar
• Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014;15(1):69-77
   PubMed Web of Science ®Google Scholar
• Rituximab with or without lenalidomide in treating patients with previously untreated follicular lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01307605
   Google Scholar